KPTI · Nasdaq
Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.
Karyopharm Therapeutics Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). The case number is 26-90827 (ARP) and the case is styled as In re Karyopharm Therapeutics Inc., et al. Additional information regarding the Cases is available at: https://cases.stretto.com/KPTI. The documents and other information on this website are not part of this Form 12b-25 and are not incorporated by reference. As previously announced, on November 2, 2026, prior to the filing of the Bankruptcy Petitions, the Debtors entered into a Restructuring Support Agreement (the “Restructuring Support Agreement”) with Ayrmid Ltd. (“Ayrmid”) and the other parties thereto, which provides for Ayrmid to serve as the stalking horse bidder for a merger between Ayrmid and the reorganized Company, subject to higher or otherwise better bids. The Restructuring Support Agreement contemplates that the transactions will be implemented through the Debtors’ Joint Prepackaged Chapter 11 Plan of Reorganization filed on November 2, 2026 (the “Prepackaged Plan”), under which the Company’s existing equity interests will be cancelled without any distribution
NT 10-Q, filed 2026-11-13 · acquisition or merger
Karyopharm Therapeutics Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). The case number is 26-90827 (ARP) and the case is styled as In re Karyopharm Therapeutics Inc., et al. Additional information regarding the Cases is available at: https://cases.stretto.com/KPTI. The documents and other information on this website are not part of this Form 12b-25 and are not incorporated by reference. As previously announced, on November 2, 2026, prior to the filing of the Bankruptcy Petitions, the Debtors entered into a Restructuring Support Agreement (the “Restructuring Support Agreement”) with Ayrmid Ltd. (“Ayrmid”) and the other parties thereto, which provides for Ayrmid to serve as the stalking horse bidder for a merger between Ayrmid and the reorganized Company, subject to higher or otherwise better bids. The Restructuring Support Agreement contemplates that the transactions will be implemented through the Debtors’ Joint Prepackaged Chapter 11 Plan of Reorganization filed on November 2, 2026 (the “Prepackaged Plan”), under which the Company’s existing equity interests will be cancelled without any distribution
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,011 are flagged today.
Every score is frozen and checked twelve months later. Across 91,468 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-14 · data from SEC EDGAR (public domain) · not
investment advice